Ezetimibe

Generic Name: Ezetimibe

Brand Names: Ezetrol, Lypqozet, Nexlizet, Roszet, Vytorin, Zetia

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₁F_₂NO_₃

CAS Number: 163222-33-1

Unique Ingredient Identifier: EOR26LQQ24

Background: Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi - this prompted studies investigating ...

Indication: Ezetimibe is indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin). It is also indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate, and to reduce elevated...

Associated Conditions: Elevated Blood Lipids, Elevated sitosterol and campesterol

Associated Therapies: -

Clinical Trials

Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects

Not Applicable

Conditions: Acute Coronary Syndrome

Interventions: Drug: simvastatin
Drug: placebo
Drug: ezetimibe

First Posted Date: 2008-07-31

Last Posted Date: 2009-02-10

Lead Sponsor: Jagiellonian University

Target Recruit Count: 100

Registration Number: NCT00725829

Locations: 🇵🇱
Institute of Cardiology, Krakow, Poland

A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)

Completed

Conditions: Hypercholesterolemia
Familial Hypercholesterolemia
Homozygous Sitosterolemia

Interventions: Drug: Ezetimibe
Drug: Ezetimibe + other lipid-lowering medication(s)

First Posted Date: 2008-06-25

Last Posted Date: 2022-02-16

Lead Sponsor: Organon and Co

Target Recruit Count: 1794

Registration Number: NCT00705211

Evaluation of the LDL-C Lowering Effects of Ezetimibe Achieved in Co-administration Therapy With Statins in an Indonesian Population (Study P04276)(COMPLETED)

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: ezetimibe
Drug: statin

First Posted Date: 2008-06-25

Last Posted Date: 2022-02-09

Lead Sponsor: Organon and Co

Target Recruit Count: 453

Registration Number: NCT00705081

A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)

Completed

Conditions: Hypercholesterolemia
Familial Hypercholesterolemia
Homozygous Sitosterolemia

Interventions: Drug: Ezetimibe
Drug: Ezetimibe + other lipid-lowering medication(s)

First Posted Date: 2008-06-25

Last Posted Date: 2022-02-16

Lead Sponsor: Organon and Co

Target Recruit Count: 11332

Registration Number: NCT00704444

Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)

Completed

Conditions: Homozygous Familial Hypercholesterolemia
Primary Hypercholesterolemia

Interventions: Drug: Ezetimibe

First Posted Date: 2008-06-25

Last Posted Date: 2022-02-09

Lead Sponsor: Organon and Co

Target Recruit Count: 4105

Registration Number: NCT00704535

Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study

Phase 4

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: ezetimibe
Drug: Placebo

First Posted Date: 2008-06-19

Last Posted Date: 2011-04-18

Lead Sponsor: Radiant Research

Target Recruit Count: 31

Registration Number: NCT00701727

Locations: 🇺🇸
Radiant Research, Chicago, Illinois, United States

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

Phase 4

Completed

Conditions: Peripheral Arterial Disease

Interventions: Drug: Ezetimibe
Drug: Niaspan
Drug: Statin therapy
Behavioral: Standard care
Drug: Aspirin
Drug: Placebo Niaspan
Drug: Placebo Ezetimibe
Drug: Clopidogrel
Procedure: Percutaneous transluminal angioplasty (PTA)

First Posted Date: 2008-05-30

Last Posted Date: 2020-02-06

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 102

Registration Number: NCT00687076

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States

A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: ABT-335
Drug: Atorvastatin
Drug: Ezetimibe

First Posted Date: 2008-05-21

Last Posted Date: 2010-10-19

Lead Sponsor: Abbott

Target Recruit Count: 18

Registration Number: NCT00681525

Locations: 🇺🇸
Site Reference ID/Investigator# 8087, Gainesville, Florida, United States

INdians Followed for INtensive Lipid Lowering Treatment and Its safetY

Phase 3

Terminated

Conditions: Hypercholesterolemia

Interventions: Drug: ezetimibe

First Posted Date: 2008-04-23

Last Posted Date: 2011-07-28

Lead Sponsor: Sunnybrook Health Sciences Centre

Target Recruit Count: 64

Registration Number: NCT00664469

Locations: 🇨🇦
Merck Frosst Canada Ltd., Kirkland, Quebec, Canada

Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Ezetimibe
Drug: Simvastatin

First Posted Date: 2008-04-07

Last Posted Date: 2024-05-21

Lead Sponsor: Organon and Co

Target Recruit Count: 151

Registration Number: NCT00653523

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy